ConductScience.org, home
A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes
API referenceFor AI assistants

Trial · NCT03292016

Results by group81

Each measurement the trial posted, group by group, in the words and numbers it posted.

21 to 40 of 81

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Mean Residence Time (MRT)Subcutaneous APO-goAPL 20 mg, APOKYN 3 mg, and APO-go 3 mg1.21Geometric Coefficient of Variation 19.3h
Mean Residence Time (MRT)APL-130277, Sublingual Thin FilmAPL 25 mg, APOKYN 4 mg, and APO-go 4 mg1.83Geometric Coefficient of Variation 41.5h
Mean Residence Time (MRT)Subcutaneous APOKYNAPL 25 mg, APOKYN 4 mg, and APO-go 4 mg1.70Geometric Coefficient of Variation 13.8h
Mean Residence Time (MRT)Subcutaneous APO-goAPL 25 mg, APOKYN 4 mg, and APO-go 4 mg1.51Geometric Coefficient of Variation 19.0h
Mean Residence Time (MRT)APL-130277, Sublingual Thin FilmAPL 30 mg, APOKYN 5 mg, and APO-go 5 mg2.15Geometric Coefficient of Variation 15.9h
Mean Residence Time (MRT)Subcutaneous APOKYNAPL 30 mg, APOKYN 5 mg, and APO-go 5 mg1.23Geometric Coefficient of Variation 3.4h
Mean Residence Time (MRT)Subcutaneous APO-goAPL 30 mg, APOKYN 5 mg, and APO-go 5 mg1.08Geometric Coefficient of Variation 35.4h
Metabolite/Parent (M/P) Drug Concentration Ratio -CmaxAPL-130277, Sublingual Thin FilmAPL 20 mg, APOKYN 3 mg and APO-go 3 mg61.6Geometric Coefficient of Variation 28.8no unit
Metabolite/Parent (M/P) Drug Concentration Ratio -CmaxSubcutaneous APOKYNAPL 20 mg, APOKYN 3 mg and APO-go 3 mg15.2Geometric Coefficient of Variation 48.9no unit
Metabolite/Parent (M/P) Drug Concentration Ratio -CmaxSubcutaneous APO-goAPL 20 mg, APOKYN 3 mg and APO-go 3 mg11.5Geometric Coefficient of Variation 4.0no unit
Metabolite/Parent (M/P) Drug Concentration Ratio -CmaxAPL-130277, Sublingual Thin FilmAPL 25 mg, APOKYN 4 mg and APO-go 4 mg32.0Geometric Coefficient of Variation 157.1no unit
Metabolite/Parent (M/P) Drug Concentration Ratio -CmaxSubcutaneous APOKYNAPL 25 mg, APOKYN 4 mg and APO-go 4 mg9.0Geometric Coefficient of Variation 149.3no unit
Metabolite/Parent (M/P) Drug Concentration Ratio -CmaxSubcutaneous APO-goAPL 25 mg, APOKYN 4 mg and APO-go 4 mg7.1Geometric Coefficient of Variation 240.3no unit
Metabolite/Parent (M/P) Drug Concentration Ratio -CmaxAPL-130277, Sublingual Thin FilmAPL 30 mg, APOKYN 5 mg and APO-go 5 mg61.2Geometric Coefficient of Variation 87.0no unit
Metabolite/Parent (M/P) Drug Concentration Ratio -CmaxSubcutaneous APOKYNAPL 30 mg, APOKYN 5 mg and APO-go 5 mg13.7Geometric Coefficient of Variation 8.2no unit
Metabolite/Parent (M/P) Drug Concentration Ratio -CmaxSubcutaneous APO-goAPL 30 mg, APOKYN 5 mg and APO-go 5 mg11.3Geometric Coefficient of Variation 47.6no unit
Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F)APL-130277, Sublingual Thin FilmAPL 20 mg, APOKYN 3 mg and APO-go 3 mg2766.9Geometric Coefficient of Variation 52.4L/h
Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F)Subcutaneous APOKYNAPL 20 mg, APOKYN 3 mg and APO-go 3 mg407.9Geometric Coefficient of Variation 33.3L/h
Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F)Subcutaneous APO-goAPL 20 mg, APOKYN 3 mg and APO-go 3 mg375.6Geometric Coefficient of Variation 32.2L/h
Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F)APL-130277, Sublingual Thin FilmAPL 25 mg, APOKYN 4 mg and APO-go 4 mg1097.8Geometric Coefficient of Variation 99.5L/h

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous pageNext page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03292016/results?page=2

API referenceFor AI assistants